Re:The first commercial gene therapy to provide an outright ...
by synapticfire on Tuesday May 10, 2016 @04:30PM
(#11670408)
I believe with so called "Orphan diseases" the economics of research and eventual market release rarely work out for private companies. I believe it takes a research phase funded by charities, grants, and tax breaks for companies to have any interest. As a family affected by this, whatever gets this to market. However, I am sure someone will make money.
I would be very interested to know how the economics of that work out. Is this a classic case of the costs and risks publicized (OSU) and the profits privatized (Avexis) ?